Pedro Nazareth Aguiar

Cost-effectiveness of Osimertinib in the First-Line Treatment of Patients With<i>EGFR</i>-Mutated Advanced Non–Small Cell Lung Cancer

Pedro Nazareth Aguiar, Benjamin Haaland, Wungki Park et al. · JAMA Oncology · 2018 · 123 citations · Full text

Pharmacy, Oncology, Pharmacoeconomics +15

Cost-effectiveness of pembrolizumab as first-line therapy for advanced non-small cell lung cancer

Mina Georgieva, Joao PsDN Lima, Pedro Nazareth Aguiar et al. · Lung Cancer · 2018 · 69 citations

Pharmacy, Oncology, Pharmacoeconomics +12

Cost-Effectiveness of Cabozantinib in the Second-Line Treatment of Advanced Hepatocellular Carcinoma

Enrique Soto‐Pérez‐de‐Celis, Pedro Nazareth Aguiar, Monica Lily Cordon et al. · Journal of the National Comprehensive Cancer Network · 2019 · 42 citations · Full text

Pharmacy, Oncology, Pharmacoeconomics +17

Addition of abiraterone, docetaxel, bisphosphonate, celecoxib or combinations to androgen-deprivation therapy (ADT) for metastatic hormone-sensitive prostate cancer (mHSPC): a network meta-analysis

Pui San Tan, Pedro Nazareth Aguiar, Benjamin Haaland et al. · Prostate Cancer and Prostatic Diseases · 2018 · 35 citations

Medicine, Oncology, Urology +16

Disparities in cancer epidemiology and care delivery among Brazilian indigenous populations

Pedro Nazareth Aguiar, Gustavo Trautman Stock, Gilberto Lopes et al. · Einstein (São Paulo) · 2016 · 29 citations · Full text

Medicine, Oncology, Cancer Epidemiology +16